Toxicokinetics of 2',3'-didehydro-3'-deoxythymidine, stavudine (D4T).

Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Toxicokinetics of 2',3'-didehydro-3'-deoxythymidine, stavudine (D4T).

Drug Metab Dispos. 1999 Jan;27(1):1-12. Unique Identifier : AIDSLINE MED/99102127
Kaul S; Dandekar KA; Schilling BE; Barbhaiya RH; Metabolism and Pharmacokinetics and Drug Safety Evaluation,; Bristol-Myers Squibb Pharmaceutical Research Institute,; Princeton, New Jersey 08543-4000, USA.

Abstract: The toxicokinetic profile of D4T was assessed by conducting in vivo and in vitro studies. In the various studies, the i.v. and oral doses ranged from 12.5 to 600 and 5 to 2000 mg/kg, respectively. D4T was rapidly absorbed with an absolute oral bioavailability ranging from 77 to 100% in various species. The steady-state volume of distribution of D4T ranged from 0.50 to 1.12 liters/kg; radioactivity was distributed in all tissues, with the highest concentrations in the organs of excretion, liver and kidneys. D4T was eliminated from the body with a half-life of 0.30 to 1.23 h. Urinary recovery of unchanged drug was species-dependent and ranged from approximately 37 to 86%. In the mass balance studies, the recovery of total radioactivity at 96 h in rats and monkeys was approximately 85% and 50%, respectively; fecal recovery was <1.5% and approximately 14% was recovered as 14CO2 in expired air in rats. The in vitro protein binding of D4T was negligible (<10%) and D4T did not induce cytochrome P-450 in rats or monkeys. D4T was metabolized to thymine and polar metabolites by the S9 and liver slices in vitro. Significant interspecies correlations were found for total body clearance, steady state of volume of distribution, and T1/2 and species body weight. The multiples of exposure observed at the various no-effect doses in the drug safety evaluation studies (10x - 1102x) affirm that adequate doses of D4T were administered to laboratory animals to discern potential human risk.

Keywords: JOURNAL ARTICLE Administration, Oral Animal Anti-HIV Agents/*ADMINISTRATION & DOSAGE/*PHARMACOKINETICS Biological Availability Comparative Study Cytochrome P-450/METABOLISM Female Half-Life Injections, Intravenous Lactation/METABOLISM Liver/DRUG EFFECTS/ENZYMOLOGY Macaca fascicularis Male Metabolic Clearance Rate Mice Pregnancy Rabbits Rats Rats, Sprague-Dawley Reverse Transcriptase Inhibitors/*ADMINISTRATION & DOSAGE/ *PHARMACOKINETICS Stavudine/*ADMINISTRATION & DOSAGE/*PHARMACOKINETICS Tissue Distribution
990530
A9950884

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .